Shares of Mersana Therapeutics MRSN remained unaffected at $10.02 after the company reported Q1 results.
Quarterly Results
Earnings per share were down 150.00% year over year to ($0.35), which beat the estimate of ($0.37).
Revenue of $11,000 lower by 99.97% year over year, which missed the estimate of $390,000.
Guidance
Mersana Therapeutics hasn't issued any earnings guidance for the time being.
Mersana Therapeutics hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: May 08, 2020
Webcast URL: https://edge.media-server.com/mmc/p/6487m4wi
Recent Stock Performance
Company's 52-week high was at $10.42
Company's 52-week low was at $1.32
Price action over last quarter: Up 10.60%
Company Profile
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
